RICHMOND, Calif., Aug. 31, 2016 /PRNewswire/ -- Sangamo
BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome
editing, announced today that Sandy
Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief
executive officer, will provide an update on the Company's
therapeutic development programs at the following conferences in
September.
- 2016 Wells Fargo Healthcare Conference, Boston, MA, September
7-8, 2016
- Dr. Macrae is scheduled to present at 9:20 am ET on Wednesday,
September 7th.
- BioCentury 23rd Annual NewsMakers in the Biotech
Industry, New York, NY,
September 9, 2016
- Dr. Macrae is scheduled to present at 9:00 am ET on Friday,
September 9th.
The presentations will be webcast live and may be accessed via a
link on the Sangamo BioSciences website in the Investor Relations
section under Events and Presentation. The presentations will be
archived on the Sangamo website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on
Engineering Genetic Cures® for monogenic and infectious
diseases by deploying its novel zinc finger DNA-binding protein
technology, in therapeutic genome editing and gene regulation, and
AAV-based gene therapy platforms. The Company's proprietary In Vivo
Protein Replacement Platform™ (IVPRP) approach is focused on
monogenic diseases, including hemophilia and lysosomal storage
disorders. Based on its proprietary IVPRP approach, Sangamo is
initiating a Phase 1/2 clinical trial for hemophilia B, the first
in vivo genome editing application cleared by the FDA. In
addition, Sangamo has a Phase 2 clinical program to evaluate the
safety and efficacy of novel ZFP Therapeutics® for the
treatment of HIV/AIDS (SB-728). The Company has also formed a
strategic collaboration with Biogen Inc. for hemoglobinopathies,
such as sickle cell disease and beta-thalassemia, and with Shire
International GmbH to develop therapeutics for Huntington's disease. It has established
strategic partnerships with companies in non-therapeutic
applications of its technology, including Dow AgroSciences and
Sigma-Aldrich Corporation. For more information about Sangamo,
visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of
Sangamo BioSciences, Inc.
Logo -
http://photos.prnewswire.com/prnh/20130102/SF35903LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-participation-at-upcoming-investor-conferences-300320906.html
SOURCE Sangamo BioSciences, Inc.